TSTickerStarGet alerts

Apimeds Pharmaceuticals US Sets 2026 Annual Meeting for December 23

Apimeds Pharmaceuticals US, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for December 23, 2026 at 9:30 a.m. Eastern Time as a completely virtual meeting. Stockholders of record as of November 20, 2026 will vote on the election of four directors, ratification of Kreit & Chiu CPA LLP as independent auditor for fiscal year 2026, and an adjournment proposal. The Board unanimously recommends voting FOR all proposals.

Share this story

Key takeaways

  • Annual Meeting: The 2026 Annual Meeting will be held virtually on December 23, 2026 at 9:30 a.m. Eastern Time via webcast at the linked primary source

  • Record Date: Stockholders of record as of November 20, 2026 are entitled to vote; 1,847,626 shares of Common Stock outstanding.

  • Director Election: Four nominees are proposed for election: Carol O'Donnell, Elona Kogan, Dr. Bennett Weintraub, and SungJoon Chae.

  • Auditor Ratification: The Board recommends ratifying Kreit & Chiu CPA LLP as independent auditor for fiscal year 2026; audit fees were $206,933 in 2025 versus $142,918 in 2024.

  • Board Composition: Upon Preferred Stock Conversion (pending NYSE American approval), three current directors are expected to resign and the Board will expand to seven directors.

  • Settlement Agreement: A Confidential Settlement and Mutual Release Agreement dated April 24, 2026, as amended, governs current board composition and the separation of the BioBusiness.

  • Proxy Solicitor: Laurel Hill Advisory Group, LLC has been engaged to assist with proxy solicitation for a fee of approximately $8,500 plus out-of-pocket expenses.

Key metrics

Shares OutstandingRecord Date November 20, 2026
1,847,626
Series A Preferred Stock OutstandingRecord Date November 20, 2026
7,477,017
Audit Fees 2025FY 2025
$206,933+45%
Audit Fees 2024FY 2024
$142,918
Quorum RequirementAnnual Meeting
33 1/3%

Disclosure changes

  • Board Composition Changes

    Under the Settlement Agreement, the Board currently consists of Ms. Kogan, Ms. O'Donnell, Dr. Weintraub and Mr. Chae. Upon completion of the Preferred Stock Conversion, Ms. Kogan, Ms. O'Donnell and Dr. Weintraub are expected to resign, and the Board is expected to expand to seven directors: four independent directors nominated by MindWave, two directors nominated by Dr. Menon (including Dr. Menon) and Mr. Chae.

    The change in control resulting from Preferred Stock Conversion will alter board composition significantly and may result in the company becoming a 'controlled company' under NYSE American listing standards
  • Executive Leadership Changes

    Dr. Vin Menon has served as Co-CEO since December 2025 and as CEO from December 2025 until May 4, 2026. SungJoon Chae has served as Co-CEO since May 4, 2026. New executive officers appointed July 1, 2026 include Capt. Sandeep Singh Yadav (COO), Vempati Subramanyeswara Sarma (CSO), and Amardeep Singh (CTO). Eric Frim serves as CFO on an advisory basis.

    Significant leadership transition occurred with new Co-CEO structure and multiple new executive appointments
  • Related Party Transactions

    On September 14, 2026, MindWave entered into a 12-month software development agreement with AQUAE Holdings Pte. Ltd. for $1,112,000 plus 20% of ALCI credits issued. AQUAE Holdings is a related party because Dr. Vin Menon, the Company's Co-CEO, is a member of its management.

    New related party transaction disclosed involving Co-CEO's affiliated entity
  • Discontinued Operations - BioBusiness

    On July 14, 2026, a subsidiary of Glucotrack, Inc. merged into Lokahi, with Lokahi surviving as a wholly owned subsidiary of Glucotrack. The Company received 37,884 shares of Glucotrack common stock and 22,691 shares of Series A preferred stock. The disposal of Lokahi represents a strategic shift and the BioBusiness is presented as a discontinued operation.

    Major strategic shift as the company disposed of its BioBusiness segment through the merger
  • Controlled Company Status

    Upon the Preferred Stock Conversion, which remains subject to NYSE American approval of the Company's new listing application, Calfin Capital Private Limited is expected to hold more than 50% of the voting power of the Company's outstanding Common Stock. If that occurs, the company may become a controlled company and may elect to rely on certain exemptions available to controlled companies.

    Potential change in control and loss of certain corporate governance protections

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow APUS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert